GOTHENBURG, Sweden, November 12, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that the company’s interim report for January–September 2026 is now available on the company’s website, www.isofolmedical.com.
The information in the press release is intended for investors.
CEO’s comments
“During the third quarter, we have focused fully on the clinical development of arfolitixorin and are, at the time of writing, in the final phase of phase Ib. We are now completing the highest dose level in the dose-escalation part and preparing for the initiation of phase II. We have just compiled and presented data generated in the study to date and continue to see positive efficacy signals, this time in a larger patient population, which is very encouraging,” says CEO Petter Segelman Lindqvist.
Third quarter, July – September 2026
- Net revenue amounted to kSEK 0 (0)
- The result for the period amounted to kSEK -11,995 (-13,064)
- Earnings per share amounted to SEK -0.04 (-0.05)
- Cash and cash equivalents on September 30 amounted to kSEK 98,087 (138,786)
January – September 2026
- Net revenue amounted to kSEK 0 (0)
- The result for the period amounted to kSEK -42,785 (-41,391)
- Earnings per share amounted to SEK -0.14 (-0.21)
Significant events during the third quarter
- On July 8, the company announced that the third dose level in the dose-escalation part of the phase Ib/II study with arfolitixorin has been completed. Following approval from the Safety Research Committee (SRC), the next dose level, 500 mg/m2, has been initiated, which also will be the highest one in the dose-escalation.
- On August 24, the company announced that additional clinical trial sites in Germany are being included in the ongoing Phase Ib/II clinical study. Isofol has added Essen University Hospital and is also preparing to shortly include another German university hospital. Both sites will begin enrolling patients for the ongoing study already during phase Ib.
Significant events after the event of the period
- On November 10, the company provided an update from the ongoing clinical phase Ib/II study of arfolitixorin. During treatment, half of the treated patients have unexpectedly become candidates for tumor surgery and no dose-limiting side effects have been noted so far. All included patients had achieved disease control.
Investor & Scientific Update in Stockholm on November 12 and in Gothenburg on November 13
Isofol has invited investors, shareholders and other stakeholders to an Investor & Scientific Update in Stockholm on November 12. The principal investigator of the company’s ongoing clinical study, Prof. Sebastian Stintzing, and pharmacology expert Prof. Frits Peters will, together with representatives from the company, provide updates on the latest developments in the development of the drug candidate arfolitixorin. An investor meeting will be held in Gothenburg on November 13 to present and discuss the key messages from the Stockholm meeting. A video recording of the event in Stockholm will be available on the company’s website afterwards.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0)739 60 12 56
Margareta Hagman, CFO
E-mail: margareta.hagman@isofolmedical.com
Phone: +46 (0)738 73 34 18
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on November 12, 2026.
About Isofol
Isofol Medical AB (publ) is a clinical stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. The company’s drug candidate arfolitixorin, a next generation folate treatment, is designed to enhance the efficacy of established standard treatments for several types of solid tumors. Arfolitixorin is currently being evaluated in phase Ib/II in colorectal cancer, the world’s third most common cancer, where there is a significant unmet medical need. Isofol is listed on Nasdaq Stockholm.
